{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T19:08:53Z","timestamp":1792696133491,"version":"4.5.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:00:00Z","timestamp":1759795200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:00:00Z","timestamp":1759795200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Canc\u00e9rop\u00f4le Nord-Ouest","award":["ORGRAFT"],"award-info":[{"award-number":["ORGRAFT"]}]},{"DOI":"10.13039\/100007380","name":"Fondation de l\u2019Avenir","doi-asserted-by":"crossref","award":["AP-RM-19-020"],"award-info":[{"award-number":["AP-RM-19-020"]}],"id":[{"id":"10.13039\/100007380","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004097","name":"Fondation ARC pour la Recherche sur le Cancer","doi-asserted-by":"publisher","award":["PJA20191209649"],"award-info":[{"award-number":["PJA20191209649"]}],"id":[{"id":"10.13039\/501100004097","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018696","name":"R\u00e9gion Normandie","doi-asserted-by":"publisher","award":["ORGATHEREX"],"award-info":[{"award-number":["ORGATHEREX"]}],"id":[{"id":"10.13039\/501100018696","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004099","name":"Ligue Contre le Cancer","doi-asserted-by":"publisher","award":["ORGAPRED"],"award-info":[{"award-number":["ORGAPRED"]}],"id":[{"id":"10.13039\/501100004099","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Ovarian cancers are the second cause of death from gynecological cancers worldwide, due to a late diagnosis combined with the development of resistance to chemotherapy. However, half of these cancers present alterations in Homologous Recombination (HR), making them sensitive to inhibitors of the PARP protein (PARPi), involved in DNA repair. Nevertheless, identifying patients who respond to chemotherapy and selecting those eligible for PARPi remains a challenge for clinicians. In this context, the use of Patient-Derived Tumor Organoids (PDTO) for predictive functional testing represents an interesting prospect for clinical decision making.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Here we established a panel of 37 long-term PDTO models of various histological subtypes from 31 ovarian cancer patients. Histological and molecular profiles of PDTO were compared to tumor sample of origin using immunohistochemical analyses and global approaches (copy number variation and transcriptomic profiling). PDTO models were exposed to standard drugs for ovarian cancer patients, including PARPi, and response was assessed using viability assay. To further define the HR status of PDTO, we performed a functional assay evaluating the ability of PDTO to initiate HR (RECAP test) using automated histo-imaging quantitative analysis of RAD51 foci, as well as an NGS analysis based on the sequencing of an HR-related genes panel to obtain a Genome Instability Score (GIS).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>We demonstrated that PDTO mimicked histological and expression of tumor markers of paired tumors. Moreover, non-negative matrix factorization approach revealed that PDTO recapitulated the transcriptomic profile of the cancer component from their sample of origin. Screening of chemotherapeutic drugs showed that PDTO exhibit heterogeneous responses, and that response of PDTO from high-grade serous ovarian carcinoma to carboplatin recapitulated patient response to first-line treatment. Additionally, the detection of HRD phenotype of PDTO using functional assay was associated with the results of the HRD test Genomic Instability Scar (GIScar).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Although larger-scale investigations are needed to confirm the predictive potential of PDTO, these results provide further evidence of the potential interest of ovarian PDTO for functional precision medicine.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13046-025-03537-x","type":"journal-article","created":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T04:44:38Z","timestamp":1759812278000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Long-term patient-derived ovarian cancer organoids closely recapitulate tumor of origin and clinical response"],"prefix":"10.1186","volume":"44","author":[{"given":"Lucie","family":"Thorel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enora","family":"Dolivet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Marie","family":"Morice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romane","family":"Florent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordane","family":"Divoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Perr\u00e9ard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucie","family":"Lecouflet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Desmartin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chlo\u00e9 Marde","family":"Alagama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Giffard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Leconte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justine","family":"Lequesne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9n\u00e9dicte","family":"Clarisse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e9lanie","family":"Briand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alimatou","family":"Traor\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Villenet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pascal","family":"Meneboo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Babin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e9opold","family":"Gaichies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Martin-Fran\u00e7oise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fran\u00e7ois Le","family":"Brun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"Rouzier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Brotin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Denoyelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Vigneron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rapha\u00ebl","family":"Leman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Vaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Castera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Blanc-Fournier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Elie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benoit","family":"Plancoulaine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Joly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthieu","family":"Meryet-Figui\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Figeac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis-Bastien","family":"Weiswald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Poulain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,7]]},"reference":[{"issue":"3","key":"3537_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"3537_CR2","first-page":"280","volume":"69","author":"S Lheureux","year":"2019","unstructured":"Lheureux S, Braunstein M, Oza AM. Epithelial ovarian cancer: evolution of management in the era of precision medicine. CA Cancer J Clin. 2019;69(4):280\u2013304.","journal-title":"CA Cancer J Clin"},{"issue":"Suppl 1Suppl 1","key":"3537_CR3","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/ijgo.13878","volume":"155","author":"JS Berek","year":"2021","unstructured":"Berek JS, Renz M, Kehoe S, Kumar L, Friedlander M. Cancer of the ovary, fallopian tube, and peritoneum: 2021 update. Int J Gynaecol Obstet. 2021;155(Suppl 1Suppl 1):61\u201385.","journal-title":"Int J Gynaecol Obstet"},{"issue":"10","key":"3537_CR4","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.annonc.2023.07.011","volume":"34","author":"A Gonzalez-Martin","year":"2023","unstructured":"Gonzalez-Martin A, Harter P, Leary A, Lorusso D, Miller RE, Pothuri B, Ray-Coquard I, Tan DSP, Bellet E, Oaknin A, et al. Newly diagnosed and relapsed epithelial ovarian cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(10):833\u201348.","journal-title":"Ann Oncol"},{"issue":"1","key":"3537_CR5","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"3537_CR6","doi-asserted-by":"publisher","first-page":"100558","DOI":"10.1016\/j.esmoop.2022.100558","volume":"7","author":"S Gulia","year":"2022","unstructured":"Gulia S, Kannan S, Ghosh J, Rath S, Maheshwari A, Gupta S. Maintenance therapy with a poly(ADP-ribose) polymerase inhibitor in patients with newly diagnosed advanced epithelial ovarian cancer: individual patient data and trial-level meta-analysis. ESMO Open. 2022;7(5):100558.","journal-title":"ESMO Open"},{"issue":"22","key":"3537_CR7","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","volume":"375","author":"MR Mirza","year":"2016","unstructured":"Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, Fabbro M, Ledermann JA, Lorusso D, Vergote I, et al. Niraparib maintenance therapy in Platinum-Sensitive, recurrent ovarian cancer. N Engl J Med. 2016;375(22):2154\u201364.","journal-title":"N Engl J Med"},{"issue":"21","key":"3537_CR8","doi-asserted-by":"publisher","first-page":"4419","DOI":"10.1158\/1078-0432.CCR-23-0898","volume":"29","author":"R Leman","year":"2023","unstructured":"Leman R, Muller E, Legros A, Goardon N, Chentli I, Atkinson A, Tranchant A, Castera L, Krieger S, Ricou A, et al. Validation of the clinical use of giscar, an Academic-developed genomic instability score predicting sensitivity to maintenance Olaparib for ovarian cancer. Clin Cancer Res. 2023;29(21):4419\u201329.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"3537_CR9","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s13046-020-01554-6","volume":"39","author":"G Federici","year":"2020","unstructured":"Federici G, Soddu S. Variants of uncertain significance in the era of high-throughput genome sequencing: a lesson from breast and ovary cancers. J Exp Clin Cancer Res. 2020;39(1):46.","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"3537_CR10","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.ccell.2021.12.004","volume":"40","author":"A Letai","year":"2022","unstructured":"Letai A, Bhola P, Welm AL. Functional precision oncology: testing tumors with drugs to identify vulnerabilities and novel combinations. Cancer Cell. 2022;40(1):26\u201335.","journal-title":"Cancer Cell"},{"issue":"4","key":"3537_CR11","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.tibtech.2017.12.005","volume":"36","author":"H Aboulkheyr Es","year":"2018","unstructured":"Aboulkheyr Es H, Montazeri L, Aref AR, Vosough M, Baharvand H. Personalized cancer medicine: an organoid approach. Trends Biotechnol. 2018;36(4):358\u201371.","journal-title":"Trends Biotechnol"},{"issue":"7","key":"3537_CR12","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1038\/s12276-024-01272-5","volume":"56","author":"L Thorel","year":"2024","unstructured":"Thorel L, Perreard M, Florent R, Divoux J, Coffy S, Vincent A, Gaggioli C, Guasch G, Gidrol X, Weiswald LB, et al. Patient-derived tumor organoids: a new avenue for preclinical research and precision medicine in oncology. Exp Mol Med. 2024;56(7):1531\u201351.","journal-title":"Exp Mol Med"},{"issue":"9","key":"3537_CR13","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1016\/j.ccell.2021.07.020","volume":"39","author":"V Veninga","year":"2021","unstructured":"Veninga V, Voest EE. Tumor organoids: opportunities and challenges to guide precision medicine. Cancer Cell. 2021;39(9):1190\u2013201.","journal-title":"Cancer Cell"},{"key":"3537_CR14","doi-asserted-by":"crossref","unstructured":"Gorski JW, Zhang Z, McCorkle JR, DeJohn JM, Wang C, Miller RW, Gallion HH, Dietrich CS, Ueland FR, Kolesar JM. Utilizing Patient-Derived epithelial ovarian cancer tumor organoids to predict carboplatin resistance. Biomedicines 2021, 9(8).","DOI":"10.3390\/biomedicines9081021"},{"issue":"6","key":"3537_CR15","doi-asserted-by":"publisher","first-page":"e104013","DOI":"10.15252\/embj.2019104013","volume":"39","author":"K Hoffmann","year":"2020","unstructured":"Hoffmann K, Berger H, Kulbe H, Thillainadarasan S, Mollenkopf HJ, Zemojtel T, Taube E, Darb-Esfahani S, Mangler M, Sehouli J, et al. Stable expansion of high-grade serous ovarian cancer organoids requires a low-Wnt environment. EMBO J. 2020;39(6):e104013.","journal-title":"EMBO J"},{"issue":"3","key":"3537_CR16","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/j.ygyno.2020.03.026","volume":"157","author":"H Chen","year":"2020","unstructured":"Chen H, Gotimer K, De Souza C, Tepper CG, Karnezis AN, Leiserowitz GS, Chien J, Smith LH. Short-term organoid culture for drug sensitivity testing of high-grade serous carcinoma. Gynecol Oncol. 2020;157(3):783\u201392.","journal-title":"Gynecol Oncol"},{"issue":"11","key":"3537_CR17","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1158\/2159-8290.CD-18-0474","volume":"8","author":"SJ Hill","year":"2018","unstructured":"Hill SJ, Decker B, Roberts EA, Horowitz NS, Muto MG, Worley MJ Jr., Feltmate CM, Nucci MR, Swisher EM, Nguyen H, et al. Prediction of DNA repair inhibitor response in Short-Term Patient-Derived ovarian cancer organoids. Cancer Discov. 2018;8(11):1404\u201321.","journal-title":"Cancer Discov"},{"issue":"11","key":"3537_CR18","doi-asserted-by":"publisher","first-page":"107762","DOI":"10.1016\/j.celrep.2020.107762","volume":"31","author":"CJ de Witte","year":"2020","unstructured":"de Witte CJ, Espejo Valle-Inclan J, Hami N, Lohmussaar K, Kopper O, Vreuls CPH, Jonges GN, van Diest P, Nguyen L, Clevers H, et al. Patient-Derived ovarian cancer organoids mimic clinical response and exhibit heterogeneous Inter- and intrapatient drug responses. Cell Rep. 2020;31(11):107762.","journal-title":"Cell Rep"},{"issue":"1","key":"3537_CR19","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.ygyno.2019.05.005","volume":"154","author":"Y Maru","year":"2019","unstructured":"Maru Y, Tanaka N, Itami M, Hippo Y. Efficient use of patient-derived organoids as a preclinical model for gynecologic tumors. Gynecol Oncol. 2019;154(1):189\u201398.","journal-title":"Gynecol Oncol"},{"issue":"5","key":"3537_CR20","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1038\/s41591-019-0422-6","volume":"25","author":"O Kopper","year":"2019","unstructured":"Kopper O, de Witte CJ, Lohmussaar K, Valle-Inclan JE, Hami N, Kester L, Balgobind AV, Korving J, Proost N, Begthel H, et al. An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity. Nat Med. 2019;25(5):838\u201349.","journal-title":"Nat Med"},{"key":"3537_CR21","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/s42003-019-0305-x","volume":"2","author":"N Phan","year":"2019","unstructured":"Phan N, Hong JJ, Tofig B, Mapua M, Elashoff D, Moatamed NA, Huang J, Memarzadeh S, Damoiseaux R, Soragni A. A simple high-throughput approach identifies actionable drug sensitivities in patient-derived tumor organoids. Commun Biol. 2019;2:78.","journal-title":"Commun Biol"},{"issue":"12","key":"3537_CR22","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1016\/j.devcel.2023.04.012","volume":"58","author":"W Senkowski","year":"2023","unstructured":"Senkowski W, Gall-Mas L, Falco MM, Li Y, Lavikka K, Kriegbaum MC, Oikkonen J, Bulanova D, Pietras EJ, Vossgrone K, et al. A platform for efficient establishment and drug-response profiling of high-grade serous ovarian cancer organoids. Dev Cell. 2023;58(12):1106\u201321. e1107.","journal-title":"Dev Cell"},{"issue":"3","key":"3537_CR23","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1007\/s00432-024-05654-0","volume":"150","author":"H Hu","year":"2024","unstructured":"Hu H, Sun C, Chen J, Li Z. Organoids in ovarian cancer: a platform for disease modeling, precision medicine, and drug assessment. J Cancer Res Clin Oncol. 2024;150(3):146.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"3537_CR24","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1186\/s12885-024-12429-w","volume":"24","author":"L Thorel","year":"2024","unstructured":"Thorel L, Divoux J, Lequesne J, Babin G, Morice PM, Florent R, Desmartin G, Lecouflet L, Marde Alagama C, Leconte A, et al. The OVAREX study: establishment of ex vivo ovarian cancer models to validate innovative therapies and to identify predictive biomarkers. BMC Cancer. 2024;24(1):701.","journal-title":"BMC Cancer"},{"issue":"1","key":"3537_CR25","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1186\/s13046-023-02809-8","volume":"42","author":"L Thorel","year":"2023","unstructured":"Thorel L, Morice PM, Paysant H, Florent R, Babin G, Thomine C, Perreard M, Abeilard E, Giffard F, Brotin E, et al. Comparative analysis of response to treatments and molecular features of tumor-derived organoids versus cell lines and PDX derived from the same ovarian clear cell carcinoma. J Exp Clin Cancer Res. 2023;42(1):260.","journal-title":"J Exp Clin Cancer Res"},{"issue":"4","key":"3537_CR26","doi-asserted-by":"publisher","first-page":"e1004873","DOI":"10.1371\/journal.pcbi.1004873","volume":"12","author":"E Talevich","year":"2016","unstructured":"Talevich E, Shain AH, Botton T, Bastian BC. CNVkit: Genome-Wide copy number detection and visualization from targeted DNA sequencing. PLoS Comput Biol. 2016;12(4):e1004873.","journal-title":"PLoS Comput Biol"},{"issue":"18","key":"3537_CR27","doi-asserted-by":"publisher","first-page":"4816","DOI":"10.1158\/1078-0432.CCR-14-0571","volume":"20","author":"KA Naipal","year":"2014","unstructured":"Naipal KA, Verkaik NS, Ameziane N, van Deurzen CH, Ter Brugge P, Meijers M, Sieuwerts AM, Martens JW, O\u2019Connor MJ, Vrieling H, et al. Functional ex vivo assay to select homologous recombination-deficient breast tumors for PARP inhibitor treatment. Clin Cancer Res. 2014;20(18):4816\u201326.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"3537_CR28","doi-asserted-by":"publisher","first-page":"16878","DOI":"10.1038\/s41598-017-17204-5","volume":"7","author":"P Bankhead","year":"2017","unstructured":"Bankhead P, Loughrey MB, Fernandez JA, Dombrowski Y, McArt DG, Dunne PD, McQuaid S, Gray RT, Murray LJ, Coleman HG, et al. QuPath: open source software for digital pathology image analysis. Sci Rep. 2017;7(1):16878.","journal-title":"Sci Rep"},{"issue":"1","key":"3537_CR29","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/s41592-020-01018-x","volume":"18","author":"C Stringer","year":"2021","unstructured":"Stringer C, Wang T, Michaelos M, Pachitariu M. Cellpose: a generalist algorithm for cellular segmentation. Nat Methods. 2021;18(1):100\u20136.","journal-title":"Nat Methods"},{"key":"3537_CR30","doi-asserted-by":"crossref","unstructured":"Schmidt U, Weigert M, Broaddus C, Myers G: Cell detection with star-convex polygons. In:. 2018, Proceedings, Part II 11: 2018: Springer; 2018: 265\u2013273.","DOI":"10.1007\/978-3-030-00934-2_30"},{"key":"3537_CR31","doi-asserted-by":"publisher","first-page":"e453","DOI":"10.7717\/peerj.453","volume":"2","author":"S van der Walt","year":"2014","unstructured":"van der Walt S, Schonberger JL, Nunez-Iglesias J, Boulogne F, Warner JD, Yager N, Gouillart E, Yu T. scikit-image c: scikit-image: image processing in python. PeerJ. 2014;2:e453.","journal-title":"PeerJ"},{"key":"3537_CR32","unstructured":"Xuan G, Zhang W, Chai P. EM algorithms of Gaussian mixture model and hidden Markov model. In: Proceedings 2001 international conference on image processing (Cat No 01CH37205): 2001: IEEE; 2001:145\u2013148."},{"key":"3537_CR33","unstructured":"Jolliffe IT. Principal component analysis and factor analysis. Principal Compon Anal 2002:150\u201366."},{"issue":"6","key":"3537_CR34","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1097\/PGP.0b013e318273fd07","volume":"32","author":"D DeLair","year":"2013","unstructured":"DeLair D, Han G, Irving JA, Leung S, Ewanowich CA, Longacre TA, Gilks CB, Soslow RA. HNF-1beta in ovarian carcinomas with serous and clear cell change. Int J Gynecol Pathol. 2013;32(6):541\u20136.","journal-title":"Int J Gynecol Pathol"},{"key":"3537_CR35","doi-asserted-by":"crossref","unstructured":"Thorel L, Elie N, Morice PM, Weiswald LB, Florent R, Perreard M, Giffard F, Ricou A, Leman R, Babin G et al. Automated scoring to assess RAD51-mediated homologous recombination in ovarian patient-derived tumor organoids. Lab Invest 2025:104097.","DOI":"10.1016\/j.labinv.2025.104097"},{"issue":"4","key":"3537_CR36","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/j.stemcr.2020.03.004","volume":"14","author":"N Maenhoudt","year":"2020","unstructured":"Maenhoudt N, Defraye C, Boretto M, Jan Z, Heremans R, Boeckx B, Hermans F, Arijs I, Cox B, Van Nieuwenhuysen E, et al. Developing organoids from ovarian cancer as experimental and preclinical models. Stem Cell Rep. 2020;14(4):717\u201329.","journal-title":"Stem Cell Rep"},{"issue":"1","key":"3537_CR37","doi-asserted-by":"publisher","first-page":"12581","DOI":"10.1038\/s41598-020-69488-9","volume":"10","author":"Y Nanki","year":"2020","unstructured":"Nanki Y, Chiyoda T, Hirasawa A, Ookubo A, Itoh M, Ueno M, Akahane T, Kameyama K, Yamagami W, Kataoka F, et al. Patient-derived ovarian cancer organoids capture the genomic profiles of primary tumours applicable for drug sensitivity and resistance testing. Sci Rep. 2020;10(1):12581.","journal-title":"Sci Rep"},{"key":"3537_CR38","doi-asserted-by":"crossref","unstructured":"Bi J, Newtson AM, Zhang Y, Devor EJ, Samuelson MI, Thiel KW, Leslie KK. Successful Patient-Derived Organoid Culture of Gynecologic Cancers for Disease Modeling and Drug Sensitivity Testing. Cancers (Basel). 2021;13(12).","DOI":"10.3390\/cancers13122901"},{"issue":"13","key":"3537_CR39","doi-asserted-by":"publisher","first-page":"16866","DOI":"10.18632\/oncotarget.7619","volume":"7","author":"H Cheng","year":"2016","unstructured":"Cheng H, Wang S, Feng R. STIM1 plays an important role in TGF-beta-induced suppression of breast cancer cell proliferation. Oncotarget. 2016;7(13):16866\u201378.","journal-title":"Oncotarget"},{"key":"3537_CR40","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/1471-2164-8-98","volume":"8","author":"P Ranganathan","year":"2007","unstructured":"Ranganathan P, Agrawal A, Bhushan R, Chavalmane AK, Kalathur RK, Takahashi T, Kondaiah P. Expression profiling of genes regulated by TGF-beta: differential regulation in normal and tumour cells. BMC Genomics. 2007;8:98.","journal-title":"BMC Genomics"},{"issue":"1","key":"3537_CR41","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41416-020-0875-x","volume":"123","author":"CE Ford","year":"2020","unstructured":"Ford CE, Werner B, Hacker NF, Warton K. The untapped potential of Ascites in ovarian cancer research and treatment. Br J Cancer. 2020;123(1):9\u201316.","journal-title":"Br J Cancer"},{"key":"3537_CR42","doi-asserted-by":"crossref","unstructured":"Arias-Diaz AE, Ferreiro-Pantin M, Barbazan J, Perez-Beliz E, Ruiz-Banobre J, Casas-Arozamena C, Muinelo-Romay L, Lopez-Lopez R, Vilar A, Curiel T et al. Ascites-Derived organoids to depict platinum resistance in gynaecological serous carcinomas. Int J Mol Sci 2023, 24(17).","DOI":"10.3390\/ijms241713208"},{"issue":"25","key":"3537_CR43","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","volume":"381","author":"I Ray-Coquard","year":"2019","unstructured":"Ray-Coquard I, Pautier P, Pignata S, Perol D, Gonzalez-Martin A, Berger R, Fujiwara K, Vergote I, Colombo N, Maenpaa J, et al. Olaparib plus bevacizumab as First-Line maintenance in ovarian cancer. N Engl J Med. 2019;381(25):2416\u201328.","journal-title":"N Engl J Med"},{"key":"3537_CR44","doi-asserted-by":"publisher","first-page":"111026","DOI":"10.1016\/j.radonc.2025.111026","volume":"210","author":"M Perreard","year":"2025","unstructured":"Perreard M, Florent R, Divoux J, Bastit V, Lecouflet L, Desmartin G, Guillemot S, Ibazizene L, Elie N, Brotin E, et al. Use of patient-derived tumor organoids from head and neck squamous cell carcinoma for the evaluation of the differential effect of carbon ions over X-rays. Radiother Oncol. 2025;210:111026.","journal-title":"Radiother Oncol"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-025-03537-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-025-03537-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-025-03537-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T17:05:34Z","timestamp":1759856734000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-025-03537-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,7]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3537"],"URL":"https:\/\/doi.org\/10.1186\/s13046-025-03537-x","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,7]]},"assertion":[{"value":"1 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent forms were signed by all patients and were obtained either by the Biological Resources Center \u2018OvaRessources\u2019, which has received NF 96 900 accreditation (N\u00b0 2016\/72860.1) or in the context of the \u2018OVAREX\u2019 clinical trial (N\u00b0ID-RCB: 2018-A02152-53, NCT03831230) [], in accordance with ethical committee and European law.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"282"}}